Mehra Golshan, MD, MBA
Professor of Surgery (Oncology); Deputy Chief Medical Officer for Surgical Services, Smilow Cancer Hospital; Executive Vice Chair, Surgery; Clinical Director of Breast Program, Yale Cancer Center
Research & Publications
Biography
News
Research Summary
Dr. Golshan is a leader in the research with over 140 peer reviewed publications. He has led numerous Phase I, II and III clinical trials and translational science innovations impacting the treatment options and outcomes for women.
Coauthors
Research Interests
Breast
Selected Publications
- Exploring the impact of exercise and mind-body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery.Knoerl R, Giobbie-Hurder A, Sannes TS, Chagpar AB, Dillon D, Dominici LS, Frank ES, Golshan M, McTiernan A, Rhei E, Tolaney SM, Winer EP, Yung RL, Irwin ML, Ligibel JA. Exploring the impact of exercise and mind-body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery. Supportive Care In Cancer : Official Journal Of The Multinational Association Of Supportive Care In Cancer 2022, 30: 2027-2036. PMID: 34648061, DOI: 10.1007/s00520-021-06617-8.
- Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators.Schreiber KL, Zinboonyahgoon N, Flowers KM, Hruschak V, Fields KG, Patton ME, Schwartz E, Azizoddin D, Soens M, King T, Partridge A, Pusic A, Golshan M, Edwards RR. Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators. Annals Of Surgical Oncology 2021, 28: 5015-5038. PMID: 33452600, PMCID: PMC8280248, DOI: 10.1245/s10434-020-09479-2.
- Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.Filho OM, Stover DG, Asad S, Ansell PJ, Watson M, Loibl S, Geyer CE, Bae J, Collier K, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans WF. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. JAMA Oncology 2021, 7: 603-608. PMID: 33599688, PMCID: PMC7893540, DOI: 10.1001/jamaoncol.2020.7310.
- Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance).Weiss A, Campbell J, Ballman KV, Sikov WM, Carey LA, Hwang ES, Poppe MM, Partridge AH, Ollila DW, Golshan M. Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Annals Of Surgical Oncology 2021, 28: 5960-5971. PMID: 33821344, PMCID: PMC8532250, DOI: 10.1245/s10434-021-09897-w.
- ASO Author Reflections: Accurately Predicting Nodal pCR Holds the Key to Axillary Surgery De-escalation Strategies.Weiss A, Golshan M, Ollila DW. ASO Author Reflections: Accurately Predicting Nodal pCR Holds the Key to Axillary Surgery De-escalation Strategies. Annals Of Surgical Oncology 2021, 28: 5972-5973. PMID: 33851312, DOI: 10.1245/s10434-021-09953-5.
- Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy.Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.
- Omission of Surgical Axillary Lymph Node Staging in Patients with Tubular Breast Cancer.Özkurt E, Wong S, Rhei E, Golshan M, Brock J, Barbie TU. Omission of Surgical Axillary Lymph Node Staging in Patients with Tubular Breast Cancer. Annals Of Surgical Oncology 2021, 28: 2589-2598. PMID: 33078312, DOI: 10.1245/s10434-020-09223-w.
- ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance).Weiss A, Campbell J, Ballman KV, Sikov WM, Carey LA, Hwang ES, Poppe MM, Partridge AH, Ollila DW, Golshan M. ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Annals Of Surgical Oncology 2021, 28: 436-437. PMID: 33993374, DOI: 10.1245/s10434-021-10005-1.
- Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program.Pak LM, Purad CC, Nadipally S, Rao MP, Mukherjee S, Hegde SKB, Golshan M. Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program. Annals Of Surgical Oncology 2021, 28: 7006-7013. PMID: 34215953, DOI: 10.1245/s10434-021-10366-7.
- Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer.Saridakis A, Berger ER, Harigopal M, Park T, Horowitz N, Le Blanc J, Zanieski G, Chagpar A, Greenup R, Golshan M, Lannin DR. Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer. Annals Of Surgical Oncology 2021, 28: 5610-5616. PMID: 34426884, DOI: 10.1245/s10434-021-10518-9.
- Immunotherapy Treatment for Triple Negative Breast Cancer.Berger ER, Park T, Saridakis A, Golshan M, Greenup RA, Ahuja N. Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals (Basel, Switzerland) 2021, 14 PMID: 34451860, PMCID: PMC8401402, DOI: 10.3390/ph14080763.
- Correction to: Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators.Schreiber KL, Zinboonyahgoon N, Mikayla Flowers K, Hruschak V, Fields KG, Patton ME, Schwartz E, Azizoddin D, Soens M, King T, Partridge A, Pusic A, Golshan M, Edwards RR. Correction to: Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators. Annals Of Surgical Oncology 2021, 28: 896. PMID: 34401990, DOI: 10.1245/s10434-021-10658-y.
- Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery.Basu SS, Stopka SA, Abdelmoula WM, Randall EC, Gimenez-Cassina Lopez B, Regan MS, Calligaris D, Lu FF, Norton I, Mallory MA, Santagata S, Dillon DA, Golshan M, Agar NYR. Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery. NPJ Breast Cancer 2021, 7: 116. PMID: 34504095, PMCID: PMC8429658, DOI: 10.1038/s41523-021-00318-5.
- ASO Visual Abstract: Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program.Pak LM, Purad CC, Nadipally S, Rao MP, Mukherjee S, Hegde SKB, Golshan M. ASO Visual Abstract: Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program. Annals Of Surgical Oncology 2021, 28: 727-728. PMID: 34542741, DOI: 10.1245/s10434-021-10470-8.
- Surgical Management of Hereditary Breast Cancer.Berger ER, Golshan M. Surgical Management of Hereditary Breast Cancer. Genes 2021, 12 PMID: 34573353, PMCID: PMC8470490, DOI: 10.3390/genes12091371.
- The Impact of COVID-19 on Breast Surgery Fellowships.Friedrich AU, DiComo JA, Golshan M. The Impact of COVID-19 on Breast Surgery Fellowships. Current Breast Cancer Reports 2021, 1-6. PMID: 34703524, PMCID: PMC8531885, DOI: 10.1007/s12609-021-00430-2.
- ASO Author Reflections: Apocrine Breast Cancer: More Questions than Answers.Saridakis A, Berger ER, Greenup R, Golshan M, Lannin DR. ASO Author Reflections: Apocrine Breast Cancer: More Questions than Answers. Annals Of Surgical Oncology 2021 PMID: 34743280, DOI: 10.1245/s10434-021-10649-z.
- Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE, Loibl S, Stover DG. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. NPJ Breast Cancer 2021, 7: 142. PMID: 34764307, PMCID: PMC8586340, DOI: 10.1038/s41523-021-00349-y.